Serum neurofilament light chain in behavioral variant frontotemporal dementia
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
ObjectiveTo determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD). MethodsBlood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration–related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry. ResultsAt baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p = 0.0006, respectively). At baseline and follow-up, NfL correlated with functional scores of patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r = −0.5857, p < 0.0001; 95% confidence interval −0.7415 to −0.3701). For patients with AD/MCI, NfL correlated with the functional performance as well (e.g., CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r = 0.5659, p = 0.0003) but not with regional brain volumes. ConclusionsAs serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure for clinical trials. Classification of evidenceThis study provides Class III evidence that for patients with cognitive problems, serum NfL concentration discriminates bvFTD from other forms of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased CSF NfL, in both genetic and sporadic subtypes, has been associated with various progression measures, including CDR, cognition (executive functioning; neuropsychiatry unit cognitive assessment tool), behavioral symptoms (FBI), frontotemporal GM atrophy, WM tract pathophysiology, GABA-ergic deficit, and survival rates”
From The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials (2024) · cites this paper as Steinacker et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similar to what was observed in CSF, serum and plasma NfL are elevated in FTD compared to AD, but with limited utility in discriminating FTD from AD.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Increased levels of NfL in CSF and serum, indicating axonal loss, correlated with increased cognitive impairment, as has been shown previously [73, 74], with a stronger correlation in serum than in CSF.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · cited 1×
“The bvFTD group consisted of 74 patients including 27 possible and 38 probable bvFTD cases diagnosed according to international diagnostic criteria.(2,3) Genetic screening of 67 patients with bvFTD for C9orf72 repeat expansion revealed 7 carriers.”
MethodSelf-citationRissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Construction of a 3D probabilistic atlas of human cortical structures
Shattuck, D. W., Mirza, M., Adisetiyo, V., Hojatkashani, C., Salamon, G., Narr, K. L., Poldrack, R. A., Bilder, R. M., & Toga, A. W. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.031 · Cited by 1,203 · cited 1×
“The volumes of different brain regions were determined as described elsewhere.(20,28,29)”
MethodCairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · cited 1×
“At the neuropathologic level, 90% of bvFTD cases are characterized by tau or TDP-43 pathology in equal shares, and about 10% show FUS pathology.(6,7)”
BackgroundAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740 · cited 2×
“An increase ofNfL inCSF and association ofCSFNfL levels with disease severity or progression was observed before in neurodegenerative diseases such as ALS,12,24,30,31 AD,11,32,33 CreutzfeldtJakob disease,34,35 and FTLD.21,33,36–38 Studies investigating serum NfL showed that levels were strongly associated with NfL lev…”
BackgroundThe overlap of amyotrophic lateral sclerosis and frontotemporal dementia
Lomen-Hoerth, C., Anderson, T., & Miller, B. (2002) · Neurology · doi:10.1212/wnl.59.7.1077 · Cited by 699
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563
Cited by
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Blood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 351
“Using plasma NfL, poor diagnostic performance has been reported for the separation of bvFTD patients from those with AD dementia (AUC of 0.68) (Steinacker et al , 2018) (Table EV1).”
InfluentialBlood neurofilament light: a critical review of its application to neurologic disease
Barro, C., Chitnis, T., & Weiner, H. L. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51234 · Cited by 296
Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD
Watanabe, M., Nakamura, Y., Michalak, Z., Isobe, N., Barro, C., Leppert, D., Matsushita, T., Hayashi, F., Yamasaki, R., Kuhle, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008160 · Cited by 220
Baiardi, S., Quadalti, C., Mammana, A., Dellavalle, S., Zenesini, C., Sambati, L., Pantieri, R., Polischi, B., Romano, L., Suffritti, M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01093-6 · Cited by 193
“Similarly, neurofilament light chain (NfL), an unspecific marker of axonal injury, showed higher values in frontotemporal dementia (FTD) than in AD and DLB [10–12] and a strong association between the values in the CSF and blood [11].”
BackgroundResult
Metadata
- Authors
- Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., von Arnim, C. A. F., Barthel, H., Danek, A., Fassbender, K., Fliessbach, K., Foerstl, H., Grimmer, T., Huppertz, H.-J., Jahn, H., Kassubek, J., Kornhuber, J., Landwehrmeyer, B., Lauer, M., Maler, J. M., Mayer, B., Oeckl, P., Prudlo, J., Schneider, A., Volk, A. E., Wiltfang, J., Schroeter, M. L., Ludolph, A. C., Otto, M., FTLDc study group, Albrecht, F., Bisenius, S., Feneberg, E., Haefner, S., Kasper, E., Kurzwelly, D., Lampe, L., Levin, J., Lornsen, F., Luley, M., Oberstein, T., Pellkofer, H., Prix, C., Richter-Schmidinger, T., Roth, N., Sabri, O., Schachner, L., Schomburg, R., Schönecker, S., Schuemberg, K., Spottke, A., Teipel, S., Wilken, P., & Zech, H.
- Affiliations
- Universität Ulm (DE)
- From the Department of Neurology (P.S., S.A.-S., E.S., I.U., C.A.F.v.A., J. Kassubek, B.L., P.O., A.C.L., M.O.) and Institute of Epidemiology and Medical Biometry (B.M.), University of Ulm; Department of Psychiatry and Psychotherapy (J.D.-S., H.F., T.G.), Klinikum Rechts der Isar, Technical University of Munich; Department of Nuclear Medicine (H.B.), Leipzig University Hospital; Department of Neurology (A.D.), Ludwig-Maximilians-University, Munich; Department of Neurology (K.F.), Saarland University...
- ORCID
- Steinacker, Petra
- Semler, Elisa
- Uttner, Ingo
- Barthel, Henryk
- Danek, Adrian
- Fassbender, Klaus
- Fliessbach, Klaus
- Grimmer, Timo
- Huppertz, Hans-Jürgen
- Jahn, Holger
- Kassubek, Jan
- Kornhuber, Johannes
- Lauer, Martin
- Maler, Juan Manuel
- Mayer, Benjamin
- Oeckl, Patrick
- Prudlo, Johannes
- Schneider, Anja
- Volk, Alexander E.
- Wiltfang, Jens
- Schroeter, Matthias L.
- Ludolph, Albert C.
- Otto, Markus
- Albrecht, Franziska
- Feneberg, Emily
- Kasper, Elisabeth
- Levin, Johannes
- Oberstein, Timo
- Prix, Catharina
- Sabri, Osama
- Schomburg, Robert
- Schönecker, Sonja
- Spottke, Annika
- Teipel, Stefan
- Venue
- Neurology
- Published
- 2018-10-09
- Volume
- 91
- Issue
- 15
- Pages
- e1390-e1401
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2890854685
- Cited by
- 116
- References
- 45
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 14 · 2023: 16 · 2022: 20 · 2021: 20 · 2020: 21 · 2019: 10
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- serum neurofilament light chain, behavioral variant frontotemporal dementia, Alzheimer's disease, mild cognitive impairment, biomarkers, functional decline, brain atrophy, differential diagnosis, neurodegeneration, brain volumetry, Mini-Mental State Examination, frontal lobe atrophy, subcortical atrophy, disease progression
- MeSH terms
- Aged, Alzheimer Disease, Atrophy, Brain, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, Organ Size, Prospective Studies, Biomarkers, Neurofilament Proteins, Disease Progression, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum neurofilament light chain in behavioral variant frontotemporal dementia. https://app.cochat.ai/papers/10.1212/wnl.0000000000006318
- The paper
- Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., von Arnim, C. A. F., Barthel, H., Danek, A., Fassbender, K., Fliessbach, K., Foerstl, H., Grimmer, T., Huppertz, H.-J., Jahn, H., Kassubek, J., Kornhuber, J., Landwehrmeyer, B., Lauer, M., Maler, J. M., . . . Zech, H. (2018). Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. https://doi.org/10.1212/wnl.0000000000006318
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.